Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.
Rosnev S, Sterner B, Schiele P, Kolling S, Martin M, Flörcken A, Erber B, Wittenbecher F, Kofla G, Kurreck A, Lang TJL, von Einem JC, de Santis M, Pelzer U, Stintzing S, Bullinger L, Klinghammer K, Geisel D, Ochsenreither S, Frentsch M, Na IK.
Rosnev S, et al. Among authors: lang tjl.
Eur J Cancer. 2025 Jan 17;217:115252. doi: 10.1016/j.ejca.2025.115252. Online ahead of print.
Eur J Cancer. 2025.
PMID: 39848112